Medullary Breast Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An infiltrating breast carcinoma with a relatively favorable prognosis. It is an uncommon carcinoma, accounting for less than 1% of all infiltrating breast carcinomas. It is well circumscribed, with soft cut surface and often of considerable size. Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells. The malignant cells are round with abundant cytoplasm and vesicular nuclei. The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate. Glandular or tubular structures are absent. 
There are 3 clinical trials for medullary breast carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain medullary breast carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open).
ER, HER2, and PR are the most frequent gene inclusion criteria for medullary breast carcinoma clinical trials .
Radiation therapy, cyclophosphamide, and durvalumab are the most common interventions in medullary breast carcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.